-+ 0.00%
-+ 0.00%
-+ 0.00%
Changes in Hong Kong stocks | Cully Pharmaceutical-B (01672) rose nearly 2% and recently submitted asc36_37o FDC IND to treat obesity to the FDA
Share
Listen to the news

The Zhitong Finance App learned that Goli Pharmaceutical-B (01672) rose nearly 2%. As of press release, it had risen 1.36% to HK$4.46, with a turnover of HK$1.047,200.

According to the news, recently, Goli Pharmaceutical-B issued an announcement. Clarie has submitted a new drug clinical trial application (IND) for ASC36_37o FDC to the US Food and Drug Administration (FDA) to treat obesity. ASC36_37O FDC is a weekly oral fixed-dose combination (FDC) tablet of the insulin agonist polypeptide ASC36 and GLP-1R/GIPR/GCGR tri-target agonist polypeptide ASC37.

The IND submission of ASC36_37O FDC is based on recent milestones in Gli's once-a-week oral peptide pipeline. Goli has recently initiated a weekly US Phase I study on oral insulin receptor agonist polypeptide ASC36O. It is expected to obtain top-line human pharmacokinetic data for this study by the end of 2026.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.
What's Trending